Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Bayer | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is a regulatory post marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Zevalin for relapsed or refractory, CD20+, low grade B-cell non-Hodgkin's lymphoma and Mantle cell lymphoma. The objective of this study is to assess safety and efficacy of using Zevalin in clinical practice. This study is also all case investigation of which the enrollment period is five years, and all patients who received Zevalin will be recruited and followed 13 weeks after the administration.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group 1 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| [90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128) | Drug | Patients who have received Zevalin for relapsed or refractory, CD20+, low grade B-cell non-Hodgkin's lymphoma and Mantle cell lymphoma. |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of adverse drug reactions in subjects who received Zevalin | After In-111 Zevalin administration, up to 13 weeks | |
| Incidence of serious adverse events, especially secondary malignant tumors, in subjects who received Zevalin | After In-111 Zevalin administration, up to 8 years |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of adverse drug reactions in subpopulation in a variety of baseline data [such as demographic data, medical history data, clinical staging] | After In-111 Zevalin administration, up to 13 weeks | |
| Effectiveness evaluation assessment [complete remission rate, complete remission uncertain rate, partial remission rate, stable disease rate, progression disease rate] by investigator-determined overall best response |
Not provided
Inclusion Criteria:
Patients who received Zevalin for relapsed or refractory:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
400cases: This study is all case investigation of which the enrollment period is five years, and all patients who received Zevalin for relapsed or refractory, CD20+, low grade B-cell non-Hodgkin's lymphoma and Mantle cell lymphoma will be recruited.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Multiple Locations | Japan |
Not provided
| ID | Term |
|---|---|
| D008228 | Lymphoma, Non-Hodgkin |
| D020522 | Lymphoma, Mantle-Cell |
| ID | Term |
|---|---|
| D008223 | Lymphoma |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D008232 | Lymphoproliferative Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| C422802 | ibritumomab tiuxetan |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| After In-111 Zevalin administration, up to 13 weeks |
| Effectiveness evaluation assessment [progression free survival] by investigator-determined overall best response | After In-111 Zevalin administration, up to 8 years |
| Change in hemoglobin from baseline | After In-111 Zevalin administration, up to 13 weeks |
| Change in neutrophil from baseline | After In-111 Zevalin administration, up to 13 weeks |
| Change in platelet from baseline | After In-111 Zevalin administration, up to 13 weeks |
| Change in leukocyte from baseline | After In-111 Zevalin administration, up to 13 weeks |
| D008206 |
| Lymphatic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |